Compositions and methods for forming stabilized compositions with reduced csa agglomeration
US-2015258121-A1 · Sep 17, 2015 · US
Treatment and prevention of mastitis
US9314472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9314472-B2 |
| Application number | US-201314056122-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 17, 2013 |
| Priority date | Oct 17, 2012 |
| Publication date | Apr 19, 2016 |
| Grant date | Apr 19, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Treating and Preventing mastitis employing cationic steroidal antimicrobials (CSAs). Treating or preventing clinical mastitis in a mammal includes administering a cationic steroidal anti-microbial compound (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ (e.g., through the teat of the mammary organ), and/or topical application. The dairy cow can be lactating and have a somatic cell count (SCC) less than or equal to 500,000 cells/mL at the time of administering the CSA formulation. Alternatively, the dairy cow can be lactating and have a somatic cell count (SCC) greater than 500,000 cells/mL at the time of administering the CSA formulation. The dairy cow can be taken out of production during the administration of the CSA formulation for a period of time of about 3 days or less, 2 days or less, or 1 day or less.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating or preventing clinical mastitis in a mammal, comprising: administering an effective amount of a cationic steroidal anti-microbial compound (CSA) formulation that is effective in treating or preventing clinical mastitis caused by one or more different microbes, including at least clinical mastitis caused by Prototheca , to the intra-mammary organ of a mammal, the CSA formulation containing at least one CSA compound of Formula I, or a ph…
Assignees
Inventors
Classifications
- A61K31/575Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9314472B2 cover?
- Treating and Preventing mastitis employing cationic steroidal antimicrobials (CSAs). Treating or preventing clinical mastitis in a mammal includes administering a cationic steroidal anti-microbial compound (CSA) formulation to the intra-mammary organ of a mammal (e.g., a dairy cow), such as by injection into the mammary organ (e.g., through the teat of the mammary organ), and/or topical applica…
- Who is the assignee on this patent?
- Beus Chad S, Savage Paul B, Univ Brigham Young
- What technology area does this patent fall under?
- Primary CPC classification A61K31/575. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).